|
1
|
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
|
J Clin Oncol
|
2014
|
4.31
|
|
2
|
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
|
J Clin Oncol
|
2005
|
2.76
|
|
3
|
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
|
J Clin Oncol
|
2008
|
2.20
|
|
4
|
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
|
J Clin Oncol
|
2009
|
1.88
|
|
5
|
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.84
|
|
6
|
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
|
J Natl Cancer Inst
|
2010
|
1.83
|
|
7
|
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
1.74
|
|
8
|
Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping.
|
J Clin Oncol
|
2014
|
1.61
|
|
9
|
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.25
|
|
10
|
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
|
Oncologist
|
2010
|
1.22
|
|
11
|
Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
|
Clin Lung Cancer
|
2011
|
1.09
|
|
12
|
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
1.07
|
|
13
|
KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
|
J Thorac Oncol
|
2013
|
1.05
|
|
14
|
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
|
Chest
|
2005
|
1.01
|
|
15
|
Barriers and challenges to global clinical cancer research.
|
Oncologist
|
2013
|
1.01
|
|
16
|
Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma.
|
Radiother Oncol
|
2012
|
1.00
|
|
17
|
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
|
J Thorac Oncol
|
2013
|
1.00
|
|
18
|
Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.
|
Health Expect
|
2008
|
1.00
|
|
19
|
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study.
|
Am J Clin Oncol
|
2012
|
0.98
|
|
20
|
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
|
J Clin Oncol
|
2009
|
0.96
|
|
21
|
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
|
Lung Cancer
|
2011
|
0.96
|
|
22
|
Sample features associated with success rates in population-based EGFR mutation testing.
|
J Thorac Oncol
|
2014
|
0.93
|
|
23
|
Ancillary testing in lung cancer diagnosis.
|
Pulm Med
|
2012
|
0.92
|
|
24
|
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
|
J Clin Oncol
|
2007
|
0.91
|
|
25
|
Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.
|
Horm Cancer
|
2012
|
0.90
|
|
26
|
Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics.
|
Drugs Aging
|
2007
|
0.87
|
|
27
|
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.
|
Per Med
|
2009
|
0.87
|
|
28
|
How affordable are targeted therapies in non-small cell lung cancer?
|
Curr Treat Options Oncol
|
2011
|
0.85
|
|
29
|
Second-hand smoke as a predictor of smoking cessation among lung cancer survivors.
|
J Clin Oncol
|
2014
|
0.85
|
|
30
|
Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
|
J Thorac Oncol
|
2013
|
0.84
|
|
31
|
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma.
|
Cancer
|
2010
|
0.83
|
|
32
|
Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.
|
J Thorac Oncol
|
2010
|
0.83
|
|
33
|
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
|
Lung Cancer
|
2008
|
0.82
|
|
34
|
Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
|
Cancer
|
2009
|
0.81
|
|
35
|
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.
|
J Thorac Oncol
|
2014
|
0.81
|
|
36
|
Do economic evaluations of targeted therapy provide support for decision makers?
|
Am J Manag Care
|
2011
|
0.81
|
|
37
|
Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma.
|
Clin Lung Cancer
|
2009
|
0.80
|
|
38
|
Factors contributing to adjuvant therapy decisions.
|
J Thorac Oncol
|
2008
|
0.80
|
|
39
|
End-of-life home care utilization and costs in patients with advanced colorectal cancer.
|
J Community Support Oncol
|
2014
|
0.80
|
|
40
|
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
|
Lung Cancer
|
2013
|
0.80
|
|
41
|
Guidelines for health technologies: specific guidance for oncology products in Canada.
|
Value Health
|
2012
|
0.80
|
|
42
|
Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine.
|
J Thorac Oncol
|
2013
|
0.79
|
|
43
|
Do economic evaluations of targeted therapy provide support for decision makers?
|
J Oncol Pract
|
2011
|
0.78
|
|
44
|
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.77
|
|
45
|
Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor.
|
J Thorac Oncol
|
2015
|
0.77
|
|
46
|
Closing the personalized medicine information gap: HER2 test documentation practice.
|
Am J Manag Care
|
2013
|
0.77
|
|
47
|
Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.77
|
|
48
|
Targeting vascular endothelial growth factor in lung cancer.
|
J Thorac Oncol
|
2010
|
0.76
|
|
49
|
Positron emission tomography use and stage migration in lung cancer: a false sense of accomplishment?
|
J Clin Oncol
|
2012
|
0.75
|
|
50
|
Gefitinib: a consideration of cost.
|
Expert Rev Pharmacoecon Outcomes Res
|
2008
|
0.75
|